Advertisement

 

 

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.
Author Information (click to view)

Huang WY, Ho CL, Lee CC, Hsiao CW, Wu CC, Jao SW, Yang JF, Lo CH, Chen JH,


Huang WY, Ho CL, Lee CC, Hsiao CW, Wu CC, Jao SW, Yang JF, Lo CH, Chen JH, (click to view)

Huang WY, Ho CL, Lee CC, Hsiao CW, Wu CC, Jao SW, Yang JF, Lo CH, Chen JH,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2017 03 2212(3) e0174280 doi 10.1371/journal.pone.0174280
Abstract

The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage III colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage III colon carcinomas treated with radical R0 resection were reviewed. One hundred thirty two patients were treated with a FOLFOX regimen (comparison group), and 113 patients were treated with the same regimen followed by additional oral UFUR (UFUR group). The clinical characteristics and mean age of the comparison and UFUR groups were similar. Furthermore, for all study patients, DFS was not significantly different between the two groups. However, 5-year OS rates were 86.8% and 68.5% in the UFUR and comparison groups, respectively (p = 0.0107). Adding UFUR to a FOLFOX regimen was found to significantly improve the OS in patients with stage III colon cancer. UFUR as a maintenance therapy following FOLFOX regimen as an alternative therapeutic option for the treatment of stage III colon cancer patients.

Submit a Comment

Your email address will not be published. Required fields are marked *

11 + twelve =

[ HIDE/SHOW ]